The CDC's vaccine policy advisors haven't budged on new RSV guidance, remaining unconvinced that younger adults at higher ...

BridgeBio disclosed results Thursday from a Phase 1/2 study of its gene therapy for Canavan disease, an extremely rare and ...

Cost and research cuts across biotech and pharma are affecting some of the contracting companies that rely on the industry.

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...

Roche has inked a new deal with Dyno Therapeutics to develop next-generation AAV capsids for gene therapies targeting ...

Marinus Pharmaceuticals is reducing its workforce again and taking other measures to reduce costs after its epilepsy ...

Zai Lab released Phase 1a data Thursday morning as it attempts to compete with a recently approved Amgen drug. The program, ...

Plus, news about Interius BioTherapeutics, Hope Medicine, PMV Pharmaceuticals, Epitopea, Alyssum Therapeutics and a new dementia trial accelerator in the UK: Bayer exercises option to develop heart ...

MGM Resorts plans to stop covering GLP-1 weight loss shots for its employees next year, after it faced constraints in what it ...

The promise of a one-and-done CRISPR infusion is beginning to look more real than ever. On Thursday, Intellia Therapeutics ...

Novo Nordisk is continuing its crusade against compounded versions of its blockbuster weight loss drugs by petitioning the ...

GSK is presenting its case for broader use of its RSV vaccine with new data from a pair of studies in younger adults with ...